 |
|
|
|
|
|
Renagel® (sevelamer hydrochloride)
Renagel controls serum phosphorus levels without the concern of calcium or metal accumulation.
New KDOQI guidelines recommend Sevelamer as a first-line option for the reduction of phosphorus in Chronic Kidney Disease (CKD) patients on hemodialysis.1
|
 |
 |
|
|
|
|
|
|
|
|
 |
|
 |
 |
|
|
|
 |
|
|
 |
Renagel® (sevelamer hydrochloride) is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. Renagel is contraindicated in patients with hypophosphatemia or bowel obstruction. Caution should be exercised in patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders including severe constipation or major GI tract surgery. Common adverse events reported with Renagel include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, and constipation. Other events reported include pruritus, rash, fecal impaction, and intestinal obstruction. Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take Renagel. Patients should be informed to take Renagel with meals and to adhere to their prescribed diets. Please see accompanying full Prescribing Information.
|
|
|
|
|
Genzyme Corporate
